BRIEF-Shanghai Henlius Biotech Updates On Phase 1 Study Of HlX07 Anti-EGFR Antibody

Nov 26 (Reuters) - Shanghai Henlius Biotech Inc:

* SHANGHAI HENLIUS BIOTECH-PHASE 1 STUDY OF HLX07 ANTI-EGFR ANTIBODY SHOWED FAVOURABLE ANTI-TUMOR EFFECT, SUPPORTS CONDUCTING PHASE 1B/2 CLINICAL STUDY

* SHANGHAI HENLIUS BIOTECH- CLINICAL STUDY OF ANTI-PD-1 ANTIBODY HLX10 SHOWED FAVOURABLE TOLERABILITY IN PATIENTS WITH RECURRENT/METASTATIC SOLID TUMOUR

* SHANGHAI HENLIUS BIOTECH INC - HLX02 TRASTUZUMAB BIOSIMILAR MANUFACTURED IN CHINA MET PHASE 3 PRIMARY ENDPOINTS Source text for Eikon: Further company coverage: